Search
Cefozopran
go.drugbank.com/drugs/DB13667ExperimentalCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseElsulfavirine
go.drugbank.com/drugs/DB14929InvestigationalElsulfavirine is under investigation in clinical trial NCT03706898 (Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interaction...
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseFlurithromycin
go.drugbank.com/drugs/DB13338ExperimentalCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseMagnesium peroxide
go.drugbank.com/drugs/DB13486ExperimentalCategories: Drugs for Constipation, Drugs for Acid Related DisordersOleandomycin
go.drugbank.com/drugs/DB11442ExperimentalVet approvedOleandomycin is a macrolide antibiotic, though it is less effective than erythromycin. It is synthesized from strains of _Streptomyces antibioticus_.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseOportuzumab monatox
go.drugbank.com/drugs/DB05319InvestigationalVB4-845 is a fusion protein containing humanized scFv specific for the epithelial cell adhesion molecule, Ep-CAM, a tumor cell-associated target highly expressed on carcinoma cells of epithelial origin … and a truncated portion of Pseudomonas exotoxin A.
Surotomycin
go.drugbank.com/drugs/DB12076InvestigationalSurotomycin is non-inferior to vancomycin and offers a promising alternative for the treatment and prevention of C. diff infection. … It is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for the treatment of Gram-positive infections.
trans NV-04
go.drugbank.com/drugs/DB05843Experimentaltrans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial stiffness.
Muraglitazar
go.drugbank.com/drugs/DB06510InvestigationalMuraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes. … In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment is associated with a substantial reduction in triglycerides (TGs), an increase in HDL-C, and a modest decrease